RiTUXimab

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36130 publications

Refractory systemic lupus erythematosus-associated thrombocytopenia treated with avatrombopag: A case report

Refractory systemic lupus erythematosus-associated thrombocytopenia treated with avatrombopag: A case report

Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Published: April 14, 2026

Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom.

Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom.

Journal: Seminars in thrombosis and hemostasis
Published: April 14, 2026

Isolated Mental Nerve Neuropathy as the First Clinical Sign of Nodal Marginal Zone Lymphoma: A Diagnostic Challenge.

Isolated Mental Nerve Neuropathy as the First Clinical Sign of Nodal Marginal Zone Lymphoma: A Diagnostic Challenge.

Journal: The American journal of case reports
Published: April 12, 2026

Characterizing juvenile-onset systemic lupus erythematosus: clinical outcomes, disease progression, and determinants in pediatric populations.

Characterizing juvenile-onset systemic lupus erythematosus: clinical outcomes, disease progression, and determinants in pediatric populations.

Journal: ARP rheumatology
Published: April 12, 2026

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Journal: Neurology
Published: April 09, 2026

Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes.

Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes.

Journal: Clinical immunology communications
Published: April 09, 2026

Safety and efficacy of currently used drug therapies for treatment of lymphomas in patients with Sjögren's disease, a scoping review.

Safety and efficacy of currently used drug therapies for treatment of lymphomas in patients with Sjögren's disease, a scoping review.

Journal: Expert opinion on drug safety
Published: April 09, 2026

Overview of Primary Angiitis of the Central Nervous System: Current Insights.

Overview of Primary Angiitis of the Central Nervous System: Current Insights.

Journal: Archives of internal medicine research
Published: April 08, 2026

Is Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to Rituximab?

Is Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to Rituximab?

Journal: Kidney international reports
Published: April 08, 2026

Exploring the intersection: adult orbital xanthogranulomatous disease and IgG4-related disease - report of 3 cases and literature review.

Exploring the intersection: adult orbital xanthogranulomatous disease and IgG4-related disease - report of 3 cases and literature review.

Journal: Orbit (Amsterdam, Netherlands)
Published: April 08, 2026

Long-term outcomes of patients with moderate-severe pediatric systemic lupus erythematosus treated with combination rituximab and cyclophosphamide therapy: A single center cohort experience and review of literature.

Long-term outcomes of patients with moderate-severe pediatric systemic lupus erythematosus treated with combination rituximab and cyclophosphamide therapy: A single center cohort experience and review of literature.

Journal: Lupus
Published: April 08, 2026

Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare.

Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare.

Journal: Journal of medical economics
Published: April 06, 2026
Showing 1-12 of 36,130

Last Updated: 04/28/2026